Literature DB >> 11343419

Combined angiotensin and endothelin receptor blockade attenuates adverse cardiac remodeling post-myocardial infarction in the rat: possible role of transforming growth factor beta(1).

A Tzanidis1, S Lim, R D Hannan, F See, A M Ugoni, H Krum.   

Abstract

A. Tzanidis, S. Lim, R. D. Hannan, F. See, A. M. Ugoni and H. Krum. Combined Angiotensin and Endothelin Receptor Blockade Attenuates Adverse Cardiac Remodeling Post-Myocardial Infarction in the Rat: Possible Role of Transforming Growth Factor beta(1). Journal of Molecular and Cellular Cardiology (2001) 33, 969-981. Myocardial infarction (MI) is associated with activation of the vasoconstrictor peptides, angiotensin II (AngII) and endothelin-1 (ET-1), which are thought to contribute to adverse cardiac remodeling and dysfunction. The present study sought to determine whether combined AngII and ET receptor blockade improves cardiac remodeling over individual treatments in an experimental model of left ventricular myocardial infarction (LVMI) in the rat. Groups of eight female Sprague-Dawley rats were randomized at 24 h post-LVMI to 1 week treatment with either vehicle, an ET(A/B)receptor antagonist (bosentan), an AT(1)receptor antagonist (valsartan), or combined treatment. Vehicle-treated animals developed LV dysfunction with extensive accumulation of collagen type I and increased alpha(1)(I) procollagen mRNA compared to sham controls. Whilst individual receptor blockade with either bosentan or valsartan reduced LVEDP towards sham control levels, there were no significant changes to myocardial collagen deposition in comparison to vehicle. In contrast, improved ventricular function by combined treatment was associated with reduced type I collagen deposition within left ventricular non-infarct regions, as well as reduced peptide distribution and cardiac gene expression of the profibrogenic peptide, transforming growth factor beta(1)(TGF beta(1)). These data demonstrate that combined AngII and ET receptor blockade has beneficial effects on myocardial fibrogenesis over individual treatments during adverse cardiac remodeling early post-MI. Copyright 2001 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11343419     DOI: 10.1006/jmcc.2001.1361

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  10 in total

Review 1.  Diagnostic and therapeutic potential of the endothelin system in patients with chronic heart failure.

Authors:  H Krum; R Denver; A Tzanidis; P Martin
Journal:  Heart Fail Rev       Date:  2001-12       Impact factor: 4.214

2.  Losartan reduces trinitrobenzene sulphonic acid-induced colorectal fibrosis in rats.

Authors:  Dov Wengrower; Giuliana Zanninelli; Giovanni Latella; Stefano Necozione; Issa Metanes; Eran Israeli; Joseph Lysy; Mark Pines; Orit Papo; Eran Goldin
Journal:  Can J Gastroenterol       Date:  2012-01       Impact factor: 3.522

3.  Pro-remodeling peptides modulate collagen α1(I) promoter activity in rat cardiac myofibroblasts.

Authors:  Andrew Kisling; Laxmansa C Katwa
Journal:  Biochem Biophys Res Commun       Date:  2019-06-08       Impact factor: 3.575

Review 4.  Endothelin and the Cardiovascular System: The Long Journey and Where We Are Going.

Authors:  Andreas Haryono; Risa Ramadhiani; Gusty Rizky Teguh Ryanto; Noriaki Emoto
Journal:  Biology (Basel)       Date:  2022-05-16

5.  Serum transforming growth factor-beta1 as a risk stratifier of sudden cardiac death.

Authors:  Ali A Sovari; Norishige Morita; James N Weiss; Hrayr S Karagueuzian
Journal:  Med Hypotheses       Date:  2008-04-29       Impact factor: 1.538

Review 6.  Calcium signaling phenomena in heart diseases: a perspective.

Authors:  Sajal Chakraborti; Sudip Das; Pulak Kar; Biswarup Ghosh; Krishna Samanta; Saurav Kolley; Samarendranath Ghosh; Soumitra Roy; Tapati Chakraborti
Journal:  Mol Cell Biochem       Date:  2006-11-21       Impact factor: 3.842

7.  Modulation of angiotensin II signaling in the prevention of fibrosis.

Authors:  Amanda M Murphy; Alison L Wong; Michael Bezuhly
Journal:  Fibrogenesis Tissue Repair       Date:  2015-04-23

8.  Differential effects of Losartan and Atorvastatin in partial and full thickness burn wounds.

Authors:  Johanneke J Akershoek; Katrien M Brouwer; Marcel Vlig; Bouke K H L Boekema; Rob H J Beelen; Esther Middelkoop; Magda M W Ulrich
Journal:  PLoS One       Date:  2017-06-14       Impact factor: 3.240

9.  The uremic toxin adsorbent AST-120 abrogates cardiorenal injury following myocardial infarction.

Authors:  Suree Lekawanvijit; Sirinart Kumfu; Bing H Wang; Minako Manabe; Fuyuhiko Nishijima; Darren J Kelly; Henry Krum; Andrew R Kompa
Journal:  PLoS One       Date:  2013-12-13       Impact factor: 3.240

10.  Secondary Prevention Medical Therapy and Outcomes in Patients With Myocardial Infarction With Non-Obstructive Coronary Artery Disease.

Authors:  Pasquale Paolisso; Luca Bergamaschi; Giulia Saturi; Emanuela Concetta D'Angelo; Ilenia Magnani; Sebastiano Toniolo; Andrea Stefanizzi; Andrea Rinaldi; Lorenzo Bartoli; Francesco Angeli; Francesco Donati; Paola Rucci; Anna Vittoria Mattioli; Nevio Taglieri; Carmine Pizzi; Nazzareno Galiè
Journal:  Front Pharmacol       Date:  2020-01-31       Impact factor: 5.810

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.